Emergent BioSolutions (STU:ER4) COGS-to-Revenue : 0.49 (As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Emergent BioSolutions COGS-to-Revenue?

Emergent BioSolutions's Cost of Goods Sold for the three months ended in Mar. 2024 was €133 Mil. Its Revenue for the three months ended in Mar. 2024 was €269 Mil.

Emergent BioSolutions's COGS to Revenue for the three months ended in Mar. 2024 was 0.49.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Emergent BioSolutions's Gross Margin % for the three months ended in Mar. 2024 was 50.55%.

Emergent BioSolutions COGS-to-Revenue Historical Data

The historical data trend for Emergent BioSolutions's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Emergent BioSolutions COGS-to-Revenue Chart

Emergent BioSolutions Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

COGS-to-Revenue

Get a 7-Day Free Trial

0.44

0.37

0.46

0.64

0.69

Emergent BioSolutions Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
COGS-to-Revenue	Get a 7-Day Free Trial															0.97	0.58	0.67	0.69	0.49

Emergent BioSolutions COGS-to-Revenue Calculation

Emergent BioSolutions's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	646.852	/	938.091
	=	0.69

Emergent BioSolutions's COGS to Revenue for the quarter that ended in Mar. 2024 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	133.032	/	269.008
	=	0.49

Emergent BioSolutions (STU:ER4) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Emergent BioSolutions's Gross Margin % for the three months ended in Mar. 2024 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	133.032 / 269.008
	=	50.55 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Emergent BioSolutions COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Emergent BioSolutions's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Emergent BioSolutions (STU:ER4) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Emergent BioSolutions Inc (STU:ER4) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

EBS:USA ER4:Germany

Address

400 Professional Drive, Suite 400, Gaithersburg, MD, USA, 20879

Website

https://www.emergentbiosolutions.com

Emergent BioSolutions Inc offers public health products to the government and healthcare providers. The company has four main units: vaccines, which produces specialty vaccines for public health threats; devices, such as nasal sprays, skin lotions, and injections; therapeutics, which includes antibody-based treatments; and contract development and manufacturing, which brings treatments to market through collaboration with the pharmaceutical and biotechnology industries and the United States government. Most revenue comes from U.S. government purchases of vaccines, devices, and therapeutic products. The company operates in two reportable segments; the Products Segment and the Services Segment.

Emergent BioSolutions (STU:ER4) Headlines

No Headlines